Industry Overview

Human milk oligosaccharides (HMOs) market was valued at $480.0 million in 2025 and is projected to reach $1,660.0 million by 2035, expanding at a CAGR of 13.2% during 2026-2035. Human milk oligosaccharides are complex carbohydrates naturally present in human breast milk and are increasingly used in infant formula, nutritional supplements, medical nutrition, and functional foods due to their prebiotic, immune-supporting, and gut-health-promoting properties.

The rising global birth rate in emerging economies and increasing awareness regarding infant nutrition are key drivers for market growth. According to the World Health Organization (WHO), over 140 million babies are born annually worldwide, fueling demand for infant nutrition products. Additionally, increasing investments in biotechnology and precision fermentation are enhancing large-scale HMO production. Regulatory approvals by authorities such as the U.S. Food and Drug Administration (FDA) and the European Commission for various HMO ingredients are further supporting market expansion. The food & beverage, pharmaceutical, and animal nutrition industries are increasingly integrating HMOs into innovative formulations, boosting overall industry growth.

Market Dynamics

Rising Demand for Infant Nutrition and Functional Ingredients

The increasing demand for premium infant nutrition products and scientifically validated functional ingredients is a major factor driving the growth of the global human milk oligosaccharides (HMOs) market. HMOs are structurally complex carbohydrates naturally present in human breast milk and are increasingly incorporated into infant formula to replicate the nutritional and functional benefits of breastfeeding. These ingredients are recognized for their ability to support immune system development, promote beneficial gut microbiota, and enhance digestive health in infants. According to the World Health Organization, exclusive breastfeeding rates remain below 50% globally, increasing the reliance on fortified infant formulas and nutritional products that closely mimic the composition of human milk. This trend is particularly evident in developed economies and urban regions of emerging markets, where consumers are increasingly opting for premium and scientifically formulated nutrition products.

In addition to infant nutrition, the expanding focus on preventive healthcare and digestive wellness is driving the adoption of HMOs in adult nutrition, functional foods, and dietary supplements. Regulatory approvals from authorities such as the European Commission and the U.S. Food and Drug Administration for HMO molecules such as 2’-Fucosyllactose (2’-FL) and Lacto-N-neotetraose (LNnT) have accelerated commercialization across multiple applications. Leading companies, including DSM-Firmenich, BASF SE, and FrieslandCampina Ingredients, are expanding production capacities and strengthening distribution networks during 2025–2026 to meet rising global demand. Increasing consumer awareness of microbiome health and immune-supporting nutrition is expected to further support long-term market growth.

High Production Costs and Regulatory Complexities

The human milk oligosaccharides (HMOs) market faces significant challenges due to the high production costs associated with manufacturing and the complexity of regulatory approval processes. HMOs are produced through technologically advanced methods such as microbial fermentation, enzymatic synthesis, chemical synthesis, and chemoenzymatic synthesis. These production techniques require specialized biotechnology infrastructure, high-purity raw materials, and sophisticated downstream purification systems, resulting in elevated capital expenditure and operational costs. Additionally, the development of new HMO molecules requires extensive research and clinical validation to demonstrate safety and efficacy, which increases research and development expenditures for manufacturers. Smaller companies and emerging players often face barriers to scaling production due to these financial and technological constraints.

Regulatory complexities across different regions further create challenges for market participants seeking international expansion. Approval requirements for novel food ingredients vary significantly across countries, with distinct safety assessments, labeling regulations, and usage restrictions imposed by regional authorities. Delays in regulatory approvals can affect product launch timelines and increase compliance-related costs. Furthermore, supply chain disruptions in fermentation feedstocks, fluctuations in raw material prices, and rising global energy costs can adversely affect production economics and profit margins. In response, manufacturers are increasingly entering into strategic collaborations, investing in capacity expansion, and adopting cost-efficient fermentation and synthesis technologies to improve scalability and strengthen global accessibility. Continued advancements in production efficiency and harmonization of regulatory standards are expected to reduce these barriers over time.

Market Segmentation

• Based on the product type, the market is segmented into fucosylated HMOS, neutral core, sialylated HMOS, and others.
• Based on the form, the market is segmented into powder and liquid.
• Based on the application, the market is segmented into infant nutrition, functional food & beverages, nutritional supplements, medical nutrition, and animal nutrition.

Fucosylated HMOs Segment Leads the Market

The Fucosylated HMOs segment accounts for the largest share of the global human milk oligosaccharides (HMOs) market due to the strong commercial adoption of key molecules such as 2’-Fucosyllactose (2’-FL) and 3-Fucosyllactose (3-FL). These oligosaccharides are among the most extensively studied and commercially approved HMOs, primarily due to their structural similarity to components naturally present in human breast milk. Fucosylated HMOs are widely used in infant nutrition products because of their demonstrated role in supporting immune system development, improving gut microbiota composition, and reducing the adhesion of harmful pathogens in the gastrointestinal tract. Their broad applicability across infant formula, nutritional supplements, and medical nutrition products has contributed to sustained market leadership.

The segment is further supported by increasing regulatory approvals and ongoing product innovation by leading manufacturers. Companies such as DSM-Firmenich, BASF SE, and Nestlé Health Science have expanded their portfolios of fucosylated HMO ingredients and formulations between 2022 and 2026 to meet rising demand from infant formula and functional nutrition manufacturers. Additionally, the growing number of clinical studies validating the benefits of 2’-FL in immune modulation, digestive health, and cognitive development is accelerating adoption across developed and emerging markets. As production capacity expands and manufacturing costs gradually decline, the segment is expected to maintain its dominant position throughout the forecast period.

Functional Food & Beverages Segment to Record Strong Growth

The Functional Food & Beverages segment is expected to record strong growth during the forecast period due to increasing consumer demand for scientifically formulated products that support digestive health, immunity, and overall wellness. Human milk oligosaccharides are increasingly being incorporated into a variety of functional beverages, dairy products, nutritional snacks, and wellness formulations owing to their prebiotic properties and microbiome-supporting benefits. Growing consumer awareness regarding the relationship between gut health and overall health outcomes is driving food and beverage manufacturers to introduce innovative HMO-enriched products targeted at both children and adults. The expansion of preventive healthcare and wellness-focused consumption patterns is further strengthening demand in this segment.

Technological advancements in microbial fermentation and ingredient stabilization are making HMOs more commercially viable for use in mainstream food and beverage applications. Manufacturers are investing in research and development to improve the taste, stability, and scalability of HMO-based ingredients in ready-to-drink beverages, dairy alternatives, and personalized nutrition products. In addition, the rise of premium health beverages and personalized nutrition solutions is encouraging greater integration of HMOs into functional formulations. Strategic collaborations between ingredient suppliers and food manufacturers, along with increased investments in microbiome science and health-focused innovation, are expected to support the rapid expansion of the Functional Food & Beverages segment over the forecast period.

Regional Outlook

The global human milk oligosaccharides (HMOs) market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

United States Leads the Market

The United States accounts for a significant share of the global human milk oligosaccharides (HMOs) market, supported by the presence of established infant nutrition manufacturers, biotechnology companies, and advanced food ingredient developers. The country has a well-developed regulatory framework, with the U.S. Food and Drug Administration approving multiple HMO ingredients such as 2’-Fucosyllactose (2’-FL) and Lacto-N-neotetraose (LNnT) for use in infant formula, dietary supplements, and functional food applications. These approvals have enabled manufacturers to commercialize HMO-based products across a broad range of nutritional categories. In addition, the increasing focus on infant gut health, immune support, and microbiome-based nutrition continues to support market expansion in the country.

The United States also benefits from a stable consumer base and high spending on premium nutritional products. According to the United States Census Bureau and the Centers for Disease Control and Prevention, annual births in the country exceed 3.6 million, sustaining consistent demand for infant formula and early-life nutrition products. Furthermore, the country’s mature dietary supplements and functional food sectors are creating additional opportunities for HMO incorporation in adult nutrition, digestive wellness products, and medical nutrition formulations. Ongoing investments in precision fermentation, biotechnology innovation, and product development are expected to further strengthen the United States’ position in the global market.

China to Record Strong Growth

China is projected to record strong growth in the global human milk oligosaccharides (HMOs) market due to rising demand for premium infant nutrition products and increasing domestic manufacturing capabilities. The country represents one of the largest consumer bases for infant formula globally, driven by growing awareness of infant health, nutrition, and immunity. According to the National Bureau of Statistics of China, more than 9 million births have been recorded annually in recent years, supporting sustained demand for infant nutrition products. Rising disposable incomes and changing consumer preferences toward scientifically formulated and premium nutrition products are further contributing to market growth.

China is also witnessing significant investment in biotechnology and food ingredient manufacturing to reduce reliance on imported HMO ingredients. Domestic companies and international manufacturers are expanding production facilities and forming strategic partnerships to strengthen local supply chains and improve product availability. In addition, supportive regulatory developments and increasing approvals for novel food ingredients are facilitating market entry for HMO-based formulations. The expansion of e-commerce channels and modern retail infrastructure is further improving the accessibility of premium infant formula, functional foods, and nutritional supplements, positioning China as one of the fastest-growing markets globally.

Competitive Landscape

The global human milk oligosaccharides market is moderately consolidated, with leading players focusing on product innovation, fermentation technology advancements, and strategic collaborations to strengthen market positions. Major companies, such as DSM-Firmenich, FrieslandCampina Ingredients, BASF SE, Novonesis, and Kyowa Hakko Bio Co., Ltd., dominate the market through strong product portfolios, regulatory approvals, and global supply chains. Companies are increasingly investing in capacity expansion, R&D, and partnerships with infant formula and functional food manufacturers to expand commercial adoption.

Recent Developments

• In March 2026, DSM-Firmenich expanded its human milk oligosaccharides (HMOs) portfolio in Asia after receiving new regulatory approvals in China, Malaysia, and Thailand. The approvals cover 3’-SL in China and 2FL/DFL, LNT, and 6’-SL in Malaysia and Thailand, strengthening its GLYCARE portfolio and supporting advanced early-life nutrition solutions in the region.
• In January 2026, Food Standards Australia New Zealand called for public comment on an application to permit new sources of human-identical milk oligosaccharides (HiMOs), including 3-FL, LNT, 3’-SL, and 6’-SL, for use in infant formula products. This regulatory development may support new product approvals, expand commercialization opportunities, and strengthen innovation in the Human Milk Oligosaccharides market across Australia and New Zealand.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global human milk oligosaccharides (HMOs) market. Based on the availability of data, the report also includes information related to new products and relevant news.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.